Severity Patterns in COVID-19 Hospitalised Patients in Spain: I-MOVE-COVID-19 Study

Viruses. 2024 Oct 30;16(11):1705. doi: 10.3390/v16111705.

Abstract

In the frame of the I-MOVE-COVID-19 project, a cohort of 2050 patients admitted in two Spanish reference hospitals between March 2020 and December 2021 was selected and a range of clinical factor data were collected at admission to assess their impact on the risk COVID-19 severity outcomes through a multivariate adjusted analysis and nomograms. The need for ventilation and intensive care unit (ICU) admission were found to be directly associated with a higher death risk (OR 6.9 and 3.2, respectively). The clinical predictors of death were the need for ventilation and ICU, advanced age, neuromuscular disorders, thrombocytopenia, hypoalbuminemia, dementia, cancer, elevated creatin phosphokinase (CPK), and neutrophilia (OR between 1.8 and 3.5), whilst the presence of vomiting, sore throat, and cough diminished the risk of death (OR 0.5, 0.2, and 0.1, respectively). Admission to ICU was predicted by the need for ventilation, abdominal pain, and elevated lactate dehydrogenase (LDH) (OR 371.0, 3.6, and 2.2, respectively) as risk factors; otherwise, it was prevented by advanced age (OR 0.5). In turn, the need for ventilation was predicted by low oxygen saturation, elevated LDH and CPK, diabetes, neutrophilia, obesity, and elevated GGT (OR between 1.7 and 5.2), whilst it was prevented by hypertension (OR 0.5). These findings could enhance patient management and strategic interventions to combat COVID-19.

Keywords: COVID-19; ICU; SARS-CoV-2; clinical phenotype; death; severity; ventilation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19* / epidemiology
  • COVID-19* / mortality
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Intensive Care Units*
  • Male
  • Middle Aged
  • Respiration, Artificial
  • Risk Factors
  • SARS-CoV-2*
  • Severity of Illness Index*
  • Spain / epidemiology

Grants and funding

This research was funded in the framework of the I-MOVE-COVID-19 study by European Union’s Horizon 2020 Research and Innovation Programme, grant number 101003673, called “Advancing knowledge for the clinical and public health response to the novel coronavirus epidemic”.